A US$2.5bn AI drug alliance is taking shape, but what have Insilico and Bora actually agreed?
Insilico Medicine and Bora Pharmaceuticals propose an AI drug alliance worth over US$2.5 billion, but definitive agreements remain pending.
Pharma & Biotech
Pharma & Biotech
Multikine is back in Phase 3, but can CEL-SCI turn a striking subgroup signal into approval?
CEL-SCI launches a 212-patient Multikine Phase 3 study, but subgroup validation, funding and regulatory execution remain decisive.
Pharma & Biotech
Tenpoint wants Yuvezzi to open a new UK presbyopia market, but another eye drop filed first
Tenpoint Therapeutics seeks UK authorisation for Yuvezzi, testing whether a dual-agent presbyopia eye drop can build a market beyond the United States.
Pharma & Biotech
Niagen wins twin rare-disease designations, but can NB4168 turn nicotinamide riboside evidence into a medicine?
Niagen Bioscience gains U.S. and EU rare-disease designations for NB4168, but human trials and proof of efficacy still lie ahead.
Pharma & Biotech
Can engineered Treg therapy scale? Cellares and Sonoma begin a crucial manufacturing test
Cellares will automate SBT-77-7101 manufacturing as Sonoma Biotherapeutics prepares its CAR-Treg program for larger clinical trials.
Medical Devices & Diagnostics
Can a phone call uncover missed cognitive decline? CaringAI’s AAIC data offer an early answer
CaringAI’s phone-based cognitive screening matched clinician scoring in a small study, but larger validation will determine its clinical reach.
Medical Devices & Diagnostics
Hospitals have chased interoperability for decades. Concord Technologies says AI may finally unlock the workflow
A new Concord Technologies report argues that artificial intelligence can make fragmented and unstructured hospital data more usable. The opportunity is substantial, but limited survey evidence, legacy infrastructure and the need for human validation make this an operational test rather than a technological victory lap.
Medical Devices & Diagnostics
ReCET diabetes trial reaches 350 patients as Endogenex advances toward FDA submission
Endogenex, Inc. reported on July 8 that enrollment has been completed in its pivotal ReCET clinical study, a prospective, randomized, double-blinded and sham-controlled trial evaluating an investigational endoscopic procedure in adults with inadequately controlled type 2 diabetes. The study enrolled 350 participants across approximately 40 sites in the United States and Australia under a U.S.
Pharma & Biotech
Quoin Pharmaceuticals clears FDA hurdle for QRX003 peeling skin syndrome trial
Quoin Pharmaceuticals Ltd. has received U.S. Food and Drug Administration clearance for an investigational new drug application covering QRX003 in generalized inflammatory peeling skin syndrome, allowing the Nasdaq-listed rare-disease developer to initiate a Phase 2 trial in the second half of 2026. The study will enroll six to eight pediatric and adult participants in the
Medical Devices & Diagnostics
Medicaroid wins European CE mark for Hinotori surgical robot
Medicaroid Corporation has secured European CE marking under the Medical Device Regulation for its Hinotori surgical robot, clearing the Japanese system for commercialisation across European Union member states and certain other markets that recognise the certification. The decision opens another major geography for a platform that has already expanded from Japan into Singapore, Malaysia and